Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK0529 in hospitalised infants with respiratory syncytial virus infection
2017-002028-26Phase 2Completed
- Sponsor
- Ark Biosciences
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing AK0529 with Placebo (2 arms). Primary endpoint: Safety and tolerability of AK0529. Started Nov 2017; status: completed.
02
Drugs
ziresovir
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2017-002028-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002028-26.